Back

FDA grants Priority Review to Roche’s Enspryng for MOGAD

Verifying
  • FDA granted Priority Review to Roche’s Enspryng for MOGAD.
  • MOGAD is an autoimmune disease with no approved treatments.
  • Enspryng’s application received the FDA’s Priority Review designation.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.